Stock Events

Stock Events

Boundless Bio 

$2.56
1
+$0.00+0% 08:00 Today

Statistics

Day High
2.6
Day Low
2.56
52W High
3.16
52W Low
0.961
Volume
3,932
Avg. Volume
-
Mkt Cap
58.23M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.06
-0.89
-0.73
-0.56
Expected EPS
-0.56
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2023
2024
2025
0Revenue
-58.2MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.24B
CRISPR Therapeutics focuses on gene editing technologies, directly competing in the genetic medicine space similar to Boundless Bio's approach to oncology.
Editas Medicine
EDIT
Mkt Cap396.24M
Editas Medicine works on genome editing technology, which is a direct competitor to Boundless Bio's gene-targeting therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.65B
Intellia Therapeutics is involved in CRISPR/Cas9 technology, competing in the same gene editing sector as Boundless Bio.
Beam Therapeutics
BEAM
Mkt Cap2.51B
Beam Therapeutics uses base editing technology, a form of gene editing that competes with Boundless Bio's precision oncology solutions.
Allogene Therapeutics
ALLO
Mkt Cap570.06M
Allogene Therapeutics focuses on allogeneic CAR T-cell therapies, which are part of the broader field of genetic medicine, overlapping with Boundless Bio's market.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.66B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals, competing in the genetic disorder treatment market like Boundless Bio.
Fate Therapeutics
FATE
Mkt Cap281.58M
Fate Therapeutics works on programmed cellular immunotherapies, which compete with Boundless Bio's focus on innovative biotechnologies for cancer treatment.
Adaptive Biotechnologies
ADPT
Mkt Cap4.7B
Adaptive Biotechnologies focuses on the immune-driven discovery and development of treatments, competing in the personalized medicine space with Boundless Bio.

About

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
Show more...
CEO
Zachary Hornby
Employees
28
Country
United States
ISIN
US10170A1007

Listings

XNAS
US
BOLD
BOATS
BOATS
BOLD.BOATS

0 Comments

Share your thoughts

FAQ

What is Boundless Bio stock price today?▼
The current price of BOLD is $2.56 USD — it has increased by +0% in the past 24 hours. Watch Boundless Bio stock price performance more closely on the chart.
What is Boundless Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Boundless Bio stocks are traded under the ticker BOLD.
Is Boundless Bio stock price growing?▼
BOLD stock has fallen by -5.19% compared to the previous week, the month change is a -9.54% fall, over the last year Boundless Bio has showed a +108.13% increase.
What is Boundless Bio market cap?▼
Today Boundless Bio has the market capitalization of 58.23M
When is the next Boundless Bio earnings date?▼
Boundless Bio is going to release the next earnings report on November 05, 2026.
What were Boundless Bio earnings last quarter?▼
BOLD earnings for the last quarter are -1.06 USD per share, whereas the estimation was -1.06 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Boundless Bio revenue for the last year?▼
Boundless Bio revenue for the last year amounts to 0 USD.
What is Boundless Bio net income for the last year?▼
BOLD net income for the last year is -58.2M USD.
How many employees does Boundless Bio have?▼
As of September 30, 2026, the company has 28 employees.
In which sector is Boundless Bio located?▼
Boundless Bio operates in the Health & Wellness sector.
When did Boundless Bio complete a stock split?▼
Boundless Bio has not had any recent stock splits.
Where is Boundless Bio headquartered?▼
Boundless Bio is headquartered in LA JOLLA, United States.